Abstract 1352P
Background
Molecular testing has become part of modern Oncological Practice. The benefits for patient care have been demonstrated in several tumour types. There is pressure by insurers and providers to generate evidence of value in genomic profiling. The goalpost is moving as new data becomes available and as we are moving to a personalised approach.
Methods
We conducted a questionnaire survey of 130 Consultants Oncologists and Haematologists amongst our group of practitioners, who requested molecular testing for patients insured with BUPA. The aim of the study was to acquire feedback on the physicians' experience, while accessing novel molecular testing and the relevance to their practice. Patient confidentiality was respected with anonymised data collected. We received responses from 21 clinicians, which revealed a valuable insight into the current genomics' landscape.
Results
The rationale for requesting a Genomic test was in 47% of cases due to requirements within the diagnostic pathway and in 32% of cases to assess the efficacy of a surgical or oncological treatment. In 86% of cases the outcome of the test affected the treatment decision, allowing for a personalised approach. The suggestions for improving our genomic service were to offer automatic authorisation of tests in 40% of cases, or make the tests part of a structured pathway in another 40% of replies. Clinician users were aware of the list of BUPA approved genomic tests in 58% of cases. The tests most commonly used by clinicians in the survey were, based on frequency were: 1.Oncotype DX 2. Guardant 360 3. Foundation One 4. gBRCA Testing 5. Endopredict.
Conclusions
Setting up a comprehensive portfolio of approved genomic tests can assist clinicians in accessing genomic testing. A structured way of applying molecular testing to the existing pathway is the preferred option. Clinicians are asking for easy access to testing. Most importantly, in the majority of cases, the results changed the management of their patients, according to clinicians.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
BUPA.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.